Literature DB >> 31693624

18F-PSMA 1007 Uptake in Brain Metastases From Breast Cancer.

Fahad Marafi1, Arun Sasikumar2, Mahmoud Alfeeli1, Wael Fathallah3.   

Abstract

A 64-year-old woman with metastatic breast cancer on follow-up had suspicious recurrent brain metastases. She underwent F-FDG PET/CT, F-PSMA 1007 brain PET/CT, and brain MRI. F-PSMA 1007 showed intense tracer localization in the suspected recurrent brain metastasis in right parietal lobe and also picked up 2 more metastatic brain lesions, which had concurrent findings of metastasis in subsequent MRI. Our case highlights the feasibility of F-PSMA 1007 PET/CT imaging of brain metastases from nonprostate cancers. It may be used as surrogate imaging tracer for potential theranostic application using alpha or beta emitters considering its similarity to PSMA-617.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31693624     DOI: 10.1097/RLU.0000000000002821

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  4 in total

1.  Non-prostate uptake on 18F-PSMA-1007 PET/CT: a case of myeloma.

Authors:  Sowmya Veerasuri; Stewart Redman; Richard Graham; Chris Meehan; David Little
Journal:  BJR Case Rep       Date:  2020-11-03

Review 2.  Current landscape and future perspectives in preclinical MR and PET imaging of brain metastasis.

Authors:  Synnøve Nymark Aasen; Heidi Espedal; Olivier Keunen; Tom Christian Holm Adamsen; Rolf Bjerkvig; Frits Thorsen
Journal:  Neurooncol Adv       Date:  2021-10-14

Review 3.  Prostate-Specific Membrane Antigen as Target for Neuroimaging of Central Nervous System Tumors.

Authors:  Brittany M Stopa; James Crowley; Csaba Juhász; Cara M Rogers; Mark R Witcher; Jackson W Kiser
Journal:  Mol Imaging       Date:  2022-04-15       Impact factor: 3.250

4.  Duodenal Adenocarcinoma Mimicking Metastasis of Prostate Cancer on 18F-Prostate-Specific Membrane Antigen-1007 PET/CT.

Authors:  Fumihiko Soeda; Tadashi Watabe; Hiroki Kato; Motohide Uemura; Norio Nonomura
Journal:  Clin Nucl Med       Date:  2021-01       Impact factor: 10.782

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.